Neuraxpharm Group and Dizlin Pharmaceuticals have signed a global co-development agreement for Infudopa SubC.
Through this deal, both companies will be responsible for the development and commercialisation of the subcutaneous infusion belt pump, which is designed to provide continuous, precise drug delivery to patients with advanced PD.
Delivering a levodopa-carbidopa combination regimen to patients consistently, Infudopa SubC is specifically catered to those who are unable to take oral medications regularly.
This agreement marks Neuraxpharm's entry into the drug-device space, while being its first-ever combination therapy.
By commercialising Infudopa SubC, the companies hope to address this debilitating neurological condition, which currently affects more than 10 million people worldwide.
Due to the progression of symptoms, oral medication tends to lose effectiveness as the disease advances, leaving patients with disabling motor fluctations that are better treated with device-aided therapies.
According to Neuraxpharm, its collaboration with Dizlin is "a transformative advancement for patients with Parkinson's disease, ensuring access to an effective and practical therapy that helps manage symptoms."
Through this agreement, Neuraxpharm will be actively involved in the co-development of the product, while ensuring its global availability.
Meanwhile, the company will receive global exclusive commercialisation rights for Infudopa SubC in Europe, as well as any countries outside of the content where it has a direct presence.
“Our partnership with Dizlin is a powerful step towards reshaping the future of Parkinson’s care," stated Dr. Jörg-Thomas Dierks, CEO of Neuraxpharm.
"Infudopa SubC® is more than a therapy — it’s a life-changing solution, effectively and practically delivering treatment to PD patients.”
“Dizlin Pharmaceuticals is very pleased to have entered into an agreement with a well-established and highly reputable pharmaceutical company specialising in the central nervous system – specifically Parkinson’s disease – and with a strong commercial organisation," added Björn Velin, CEO of Dizlin Pharmaceuticals.
“We are committed to bringing our products to market quickly – and confident of being successful in this regard – so that more patients in the advanced stage of Parkinson’s disease can gain access to this possibility of enhancing their life quality and functioning.”
